3 assets in Superficial Urinary Bladder Carcinoma

Therapeutic assets addressing Superficial Urinary Bladder Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Superficial Urinary Bladder Carcinoma	Merck Sharp & Dohme LLC	P3	B (60)
Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain Superficial Urinary Bladder Carcinoma	Merck Sharp & Dohme LLC	P3	B (59)
Tyra-300 Superficial Urinary Bladder Carcinoma	Tyra Biosciences, Inc	P1/2	CCC (48)